Observational studyBMJ open2026
REAl world Dementia OUTcomes (READ-OUT) protocol: observational study.
Observational study in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDevelopments in blood biomarkers (BBMs) in dementia call for studies that evaluate their diagnostic, prognostic and societal implications in real-world populations. Such evidence is essential to support the safe and effective integration of BBMs into clinical practice. METHODS AND ANALYSIS: The REAl world Dementia OUTcomes study (READ-OUT) is a UK-based, multi-site study that assesses the prognostic and diagnostic utility of BBMs in people attending memory assessment services ('secondary care'). READ-OUT phase 1 is a 3-year observational study of 3165 people representative of the UK population, with up-sampling of under-represented groups and proactive recruitment to include individuals missing from secondary care memory services. Participants are over the age of 45, able to provide a blood sample and willing to consent to linkage with electronic health records. The baseline study visit includes venepuncture and questionnaire assessment of quality of life and health resource usage. A subsample of the full cohort will have further venepuncture and questionnaires at a 52-week follow-up. READ-OUT substudies will evaluate BBMs' test-retest reliability, the impact of processing delays and the feasibility of self-collected blood-spot samples. The clinical utility of BBMs will be assessed against diagnosis, outcomes from electronic health records, corollary data and health economic data. Results of the observational study discussed in this protocol will inform the design of a randomised controlled trial to test the cost-effectiveness, acceptability and clinical utility of disclosed BBM results. ETHICS AND DISSEMINATION: The study has received Research Ethics Committee approval (REC reference 24/WA/0330) and approval through the Health Research Authority/Health and Care Research Wales (IRAS project 342412). Anonymised study data will be stored on the Dementia Platform UK (DPUK) Data Portal (https://portal.dementiasplatform.uk) and made available through a managed access process, subject to the DPUK Data Access Agreement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.